NEWS REVIEW

In the News
Photodynamic Therapy Moves Closer to FDA Approval
Online Trading Community Prohibits Contact Lens Sales
Review of Optometry Moves to New Offices
 

In the News
Cole National says it lost 19 cents a share in the third quarter of its fiscal year. Cole also plans to close its 150 leased optical departments in Montgomery Ward stores by the end of January "to focus its resources on enhancing the performance of its remaining vision businesses," says the company. Cole expects to take a loss of $2 million-2.5 million for the costs to close these stores. The news comes about a month after Cole announced the return of CEO and president Jeffrey A. Cole to the company. "Over the next several months we will be re-evaluating our strategy of eliminating in-store labs from Pearle stores, as well as rethinking the media mix used to advertise Pearle's positioning," Mr. Cole adds.

VisionAmerica Inc. has entered into an agreement to sell its ophthalmic buying group, Primary Eyecare Network (PEN) of San Ramon, Calif., to HMI Buying Group, based in Vicksburg, Miss. The PEN and HMI combination now forms the largest purchasing enterprise for eye-care professionals. The new company will have more than $90 million in annual sales, HMI says.

Update your little black book: TLC The Laser Center Inc., whose U.S. headquarters are in Bethesda, Md., has changed its name to TLC Laser Eye Centers.

top

Photodynamic Therapy Moves Closer to FDA Approval
A laser-activated drug therapy that's been found to temporarily halt choroidal neovascularization in patients with the wet form of age-related macular degeneration has moved one step closer to FDA approval.

The FDA could decide in February 2000 to approve the drug Visudyne (verteporfin) for such use, co-developers CIBA Vision Ophthalmics and QLT PhotoTherapeutics Inc. say. The agency confirms that the Ophthalmic Drugs Subcommittee of the FDA's Dermatological and Ophthalmic Drugs Advisory Committee "looked favorably" on the drug in terms of its risks and benefits, and has recommended the FDA "seriously consider approval," the FDA press office says.

Visudyne is an injectible drug that's excited in the eye with a low-level, non-thermal laser light. The procedure can be performed in a doctor's office. The drug accumulates in the affected choroidal vessels and, once activated, results in halting abnormal vessel growth. Fluorescein angiography shows that Visudyne does not affect the surrounding retinal vessels, even after repeated treatments, the companies say.

Two studies in Archives of Ophthalmology report that Visudyne treatment temporarily halted fluorescein leakage from CNV in two different populations.

The first study involved 128 patients who had one treatment. Although fluorescein leakage in at least a portion of the CNV reappeared 4-12 weeks post-treatment in almost all cases, leakage had been reduced in almost half of all subjects. Eyes in which the area of any CNV leakage at three months was below baseline had better visual acuity (+0.8 line) than eyes in which CNV leakage progressed (-0.8 line).1

The second study involved a group that had repeated treatments. Again, in this group fluorescein showed CNV leakage reappearing 1-3 months after retreatment in almost all cases. However, the researchers report that leakage activity appeared to be reduced compared with baseline after multiple PDT courses.

This group was subject to one of two treatment methods vs. the five for the single-treatment group. The group who had a more intense laser pulse applied (100 J/cm2) at 20 minutes after Visudyne administration had an average visual acuity change of +0.2 lines 4-5 months after treatment. The group who had a lesser pulse applied (50-100 J/Cm2) 15 minutes after administration had an average loss of 1.0 line of vision. Also, patients with the former retreatment regimen had a lesser incidence of CNV progression than those in the latter group: 48 percent of eyes vs. 90 percent.2

More information on Visudyne is available at www.visudyne.com.

1. Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, et al. Photodynamic therapy with Verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a Phase 1 and 2 study. Arch Ophthalmol. 1999;117:1161-1173
2. Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, et al. Photodynamic therapy with Verteporfin for choroidal neovascularization caused by age-related macular degeneration results of retreatments in a Phase 1 and 2 study. Arch Ophthalmol. 1999;117:1177-1187

top

Online Trading Community Prohibits Contact Lens Sales
During the past decade, many of you have worried about patients buying their contact lenses from alternative sources without valid prescriptions or appropriate care. As more people shop online, will the Internet become the next source of concern?

eBay, the personal online trading community, has addressed this problem by forbidding the auction of contact lenses online. Since it was founded in 1995, eBay has prohibited online trading of any items that require a prescription from a licensed practitioner, company spokesman Kevin Pursglove says. However, the company noticed that some customers still listed eyeglasses and contact lenses. Meanwhile, contact lens manufacturer Wesley Jessen learned that its FreshLook ColorBlends lenses were listed for auction on eBay. The company's legal counsel requested that eBay discontinue contact lens auctions, says Dwight Akerman, O.D., WJ's director of professional services.

During the summer, eBay clarified its prohibition against the sale of prescription items, and now lists contact lenses and prescription eyewear as prohibited items, Mr. Pursglove says.  The company's web site denotes optometrists as licensed practitioners.

Whenever eBay discovers that prohibited items are up for auction, it removes them from the site and informs the seller of the violation. WJ too receives reports—about 20-30 each year—of lenses being sold at unauthorized locations such as hair salons, nail parlors and even flea markets. The company threatens legal action when necessary. WJ also limits the number of free trial lenses it provides to accounts.

Dr. Akerman says this is not a major problem. Still, he says, "We take it very seriously because we want to prevent serious eye problems occurring since people purchase these unauthorized and receive no professional supervision."

top

Review of Optometry Moves to New Offices
The editorial, sales and business offices of Review of Optometry have relocated to Newtown Square, Pa. New address is:
11 Campus Blvd.
Suite 100
Newtown Square, PA   19073

Also, all our phone numbers have changed. Our new main telephone number is 610-492-1073, and our new fax is 610-492-1049.

You may e-mail us at our new e-mail address, reviewofoptometry@jobson.com .

top

 

| | | | | |